Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
Tuan Vu, Andreas Meisel, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Rasha Aguzzi, Ahmed Enayetallah, Kathleen N. Beasley, Nishi Rampal, James F. Howard
Abstract
This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis (MP4 594600 KB).
Topics & Concepts
Complement (music)Myasthenia gravisTerminal (telecommunication)MedicineNeurologyImmunologyNeuroscienceComputer scienceChemistryBiochemistryBiologyTelecommunicationsGeneComplementationPhenotypePsychiatryMyasthenia Gravis and ThymomaPeripheral Neuropathies and DisordersPituitary Gland Disorders and Treatments